Abstract
Introduction: Neonatal severe hyperparathyroidism (NSHPT) is a rare cause of neonatal hypercalcemia caused by a loss of function mutation in the calcium-sensing receptor (CaSR). Hypercalcemia in NSHPT can be life-threatening. Maintenance of serum calcium within a safe range is the primary goal of treatment through hydration, forced diuresis, and bisphosphonate treatment, nevertheless most cases require parathyroidectomy. We report a case with NSHPT diagnosed on the first day of life (DoL) and successfully treated with cinacalcet as the first-line treatment from the 2nd DoL up to the age of 18 months. Case Report: A full-term baby evaluated for weight loss at postnatal 14th hour and found to have hypercalcemia (14.4 mg/dL, reference range [RR]: 8.0–11.3). Despite hydration and diuresis, hypercalcemia persisted. Further evaluation revealed a parathyroid hormone (PTH) level of 1,493 pg/mL (RR: 15–65) and urine Ca/Cr of 0.09 mg/mg (RR: 0.03–0.81). Cinacalcet treatment was initiated on the 2nd DoL with the diagnosis of NSHPT due to hypocalciuric hypercalcemia and elevated PTH level. Ca levels decreased to normal levels on the 7th DoL. She was discharged from hospital at postnatal day 15 on cinacalcet treatment and still continued at 18 months of age. Sequencing of CaSR revealed a novel homozygous c.1836G>A (p.G613E) mutation in the patient, for which the parents and sister were heterozygous. Conclusion: This case represents the youngest age at cinacalcet initiation and the longest duration without parathyroidectomy in a homozygous NSHPT and demonstrates that cinacalcet is an effective first-line treatment in patients who are responsive to this treatment modality and allows avoiding/delay in surgical intervention in NSHPT.
References
1.
Hendy
GN
, D’Souza-Li
L
, Yang
B
, Canaff
L
, Cole
DE
. Mutations of the calcium-sensing receptor (CASR) in familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia
. Hum Mutat
. 2000
;16
(4
):281
–96
.2.
Brown
EM
, Gamba
G
, Riccardi
D
, Lombardi
M
, Butters
R
, Kifor
O
, . Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid
. Nature
. 1993
;366
:575
–80
.3.
Gorvin
CM
. Molecular and clinical insights from studies of calcium-sensing receptor mutations
. J Mol Endocrinol
. 2019
;63
:1
–16
.4.
Marx
SJ
, Sinaii
N
. Neonatal severe hyperparathyroidism: novel insights from calcium, PTH, and the CASR gene
. J Clin Endocrinol Metabol
. 2020
;105
(4
):1061
–78
.5.
Pearce
S
, Steinmann
B
. Casting new light on the clinical spectrum of neonatal severe hyperparathyroidism
. Clin Endocrinol
. 1999
;50
(6
):691
–3
.6.
Hendy
GN
, Guarnieri
V
, Canaff
L
. Calcium-sensing receptor and associated diseases
. Prog Mol Biol Transl Sci
. 2009
;89
:31
–95
.7.
Aida
K
, Koishi
S
, Inoue
M
, Nakazato
M
, Tawata
M
, Onaya
T
. Familial hypocalciuric hypercalcemia associated with mutation in the human Ca2+-sensing receptor gene
. J Clin Endocrinol Metab
. 1995
;80
(9
):2594
–8
.8.
Al-Khalaf
FA
, Ismail
A
, Soliman
AT
, Cole
DE
, Ben-Omran
T
. Neonatal severe hyperparathyroidism: further clinical and molecular delineation
. Eur J Pediatr
. 2011
;170
(5
):625
–31
.9.
Atay
Z
, Bereket
A
, Haliloglu
B
, Abali
S
, Ozdogan
T
, Altuncu
E
, . Novel homozygous inactivating mutation of the calcium-sensing receptor gene (CASR) in neonatal severe hyperparathyroidism-lack of effect of cinacalcet
. Bone
. 2014
;64
:102
–7
.10.
Reh
CM
, Hendy
GN
, Cole
DE
, Jeandron
DD
. Neonatal hyperparathyroidism with a heterozygous calcium-sensing receptor (CASR) R185Q mutation: clinical benefit from cinacalcet
. J Clin Endocrinol Metab
. 2011
;96
(4
):E707
–12
.11.
Fisher
MM
, Cabrera
SM
, Imel
EA
. Successful treatment of neonatal severe hyperparathyroidism with cinacalcet in two patients
. Endocrinol Diabetes Metab Case Rep
. 2015
;2015
:150040
.12.
Murphy
H
, Patrick
J
, Báez-Irizarry
E
, Lacassie
Y
, Gómez
R
, Vargas
A
, . Neonatal severe hyperparathyroidism caused by homozygous mutation in CASR: a rare cause of life-threatening hypercalcemia
. Eur J Med Genet
. 2016
;59
(4
):227
–31
.13.
Waller
S
, Kurzawinski
T
, Spitz
L
, Thakker
R
, Cranston
T
, Pearce
S
, . Neonatal severe hyperparathyroidism: genotype/phenotype correlation and the use of pamidronate as rescue therapy
. Eur J Pediatr
. 2004
;163
(10
):589
–94
.14.
García Soblechero
E
, Ferrer Castillo
MT
, Jiménez Crespo
B
, Domínguez Quintero
ML
, González Fuentes
C
. Neonatal hypercalcemia due to a homozygous mutation in the calcium-sensing receptor: failure of cinacalcet
. Neonatology
. 2013
;104
(2
):104
–8
.15.
Ahmad
N
, Bahasan
M
, Al-Ghamdi
BAA
, Al-Enizi
HF
, Al-Zahrani
AS
. Neonatal severe hyperparathyroidism secondary to a novel homozygous CASR gene mutation
. Clin Cases Miner Bone Metab
. 2017
;14
(3
):354
–8
.16.
Savas-Erdeve
S
, Sagsak
E
, Keskin
M
, Magdelaine
C
, Lienhardt-Roussie
A
, Kurnaz
E
, . Treatment experience and long-term follow-up data in two severe neonatal hyperparathyroidism cases
. J Pediatr Endocrinol Metab
. 2016
;29
(9
):1103
–10
.17.
Fox
L
, Sadowsky
J
, Pringle
KP
, Kidd
A
, Murdoch
J
, Cole
DE
, . Neonatal hyperparathyroidism and pamidronate therapy in an extremely premature infant
. Pediatrics
. 2007
;120
(5
):e1350
–4
.18.
Nemeth
EF
, Fox
J
. Calcimimetic compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism
. Trends Endocrinol Metab
. 1999
;10
(2
):66
–71
.19.
Wüthrich
RP
, Martin
D
, Bilezikian
JP
. The role of calcimimetics in the treatment of hyperparathyroidism
. Eur J Clin Invest
. 2007
;37
(12
):915
–22
.20.
Peacock
M
, Bolognese
MA
, Borofsky
M
, Scumpia
S
, Sterling
LR
, Cheng
S
, . Cinacalcet treatment of primary hyper-parathyroidism: biochemical and bone densitometric outcomes in a five-year study
. J Clin Endocrinol Metab
. 2009
;94
:4860
–7
.21.
Timmers
HJ
, Karperien
M
, Hamdy
NA
, de Boer
H
, Hermus
AR
. Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a de novo inactivating mutation of the calcium-sensing receptor
. J Intern Med
. 2006
;260
(2
):177
–82
.22.
Festen-Spanjer
B
, Haring
CM
, Koster
JB
, Mudde
AH
. Correction of hypercalcaemia by cinacalcet in familial hypocalciuric hypercalcaemia
. Clin Endocrinol
. 2008
;68
(2
):324
–5
.23.
Gannon
AW
, Monk
HM
, Levine
MA
. Cinacalcet monotherapy in neonatal severe hyperparathyroidism: a case study and review
. J Clin Endocrinol Metab
. 2014
;99
(1
):7
–11
.24.
Wilhelm-Bals
A
, Parvex
P
, Magdelaine
C
, Girardin
E
. Successful use of bisphosphonate and calcimimetic in neonatal severe primary hyperparathyroidism
. Pediatrics
. 2012
;129
(3
):e812
–6
.25.
Sun
X
, Huang
L
, Wu
J
, Tao
Y
, Yang
F
. Novel homozygous inactivating mutation of the calcium-sensing receptor gene in neonatal severe hyperparathyroidism responding to cinacalcet therapy: a case report and literature review
. Medicine
. 2018
;97
:13128
.26.
Forman
TE
, Niemi
AK
, Prahalad
P
, Shi
RZ
, Nally
LM
. Cinacalcet therapy in an infant with an R185Q calcium-sensing receptor mutation causing hyperparathyroidism: a case report and review of the literature
. J Pediatr Endocrinol Metab
. 2019
;32
(3
):305
–10
.27.
Abdullayev
T
, Korkmaz
M
, Kul
M
, Koray
N
. A rare cause of neonatal hypercalcemia: neonatal severe primary hyperparathyroidism: a case report and review of the literature
. Int J Surg Case Rep
. 2020
;66
:365
–9
.28.
Capozza
M
, Chinellato
I
, Guarnieri
V
, Di Lorgi
N
, Accadia
M
, Traggiai
C
, . Case report: acute clinical presentation and neonatal management of primary hyperparathyroidism due to a novel CaSR mutation
. BMC Pediatr
. 2018
;18
(1
):340
.29.
Hashim
R
, Levine
MA
, Somasundarum
K
, Lamahewage
A
, Atapattu
N
. Neonatal severe hyperparathyroidism due to a homozygous mutation of calcium-sensing receptor; a challenging case
. Ceylon Med J
. 2019
;64
(4
):155
–7
.30.
Takada
D
, Tsukamoto
T
, Fuse
M
, Kada
S
, Yanagita
M
. The use of cinacalcet hinders the diagnosis of parathyroid carcinoma in a chronic dialysis patient: a case report
. BMC Nephrol
. 2017
;18
(1
):315
.31.
Page
LA
, Haddow
JE
. Self-limited neonatal hyperparathyroidism in familial hypocalciuric hypercalcemia
. J Pediatr
. 1987
;111
(2
):261
–4
.32.
Harris
SS
, D’Ercole
AJ
. Neonatal hyperparathyroidism: the natural course in the absence of surgical intervention
. Pediatrics
. 1989
;83
(1
):53
–6
.33.
Wilkinson
H
, James
J
. Self limiting neonatal primary hyperparathyroidism associated with familial hypocalciuric hypercalcaemia
. Arch Dis Child
. 1993
;69
(3 Spec No
):319
–21
.© 2020 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2020
You do not currently have access to this content.
